How Many People Are Allergic to Peanuts? U.S. Stats

Roughly 2 to 3 percent of Americans report having a peanut allergy, but the real number depends on how strictly you define it. A large national survey found that about 2.9 percent of U.S. adults say they are allergic to peanuts, while only about 1.8 percent have symptoms consistent with a true immune-mediated reaction, and just 1.3 percent have a physician-confirmed diagnosis. Among children, estimated prevalence sits around 2.2 percent. Those numbers have climbed steeply over the past two decades, and the gap between what people believe and what testing confirms is one of the more interesting wrinkles in allergy statistics.

The Gap Between Self-Report and Confirmed Allergy

The headline figure most often quoted is the self-reported rate, because it is the easiest to measure in population surveys. When researchers asked a nationally representative sample of U.S. adults whether they had a peanut allergy, 2.9 percent said yes. But when those same reports were filtered for symptoms that match a genuine immune reaction to peanut protein, the number dropped to 1.8 percent. Adding a further requirement of physician diagnosis brought it down to 1.3 percent.¹ Self-reported food allergy surveys have been shown to overestimate the actual rate of allergy confirmed by an oral food challenge, the gold-standard test.²

This does not mean people are making things up. Some may have had a bad experience with peanuts that was actually food intolerance rather than an immune reaction. Others may have been told by a doctor to avoid peanuts after a borderline test result, even though they were never formally diagnosed. The practical takeaway is that when you see a statistic like “3 percent of Americans are allergic to peanuts,” it is likely the upper bound. The true rate of clinically significant peanut allergy in adults probably falls closer to 1.5 to 2 percent.

How the Numbers Have Changed Over Time

Peanut allergy was relatively rare a generation ago. The best available estimates suggest that prevalence in the U.S. and Europe increased about 3.5-fold over two decades, reaching roughly 1.4 to 2 percent.³ Tracking this rise in children has been especially striking. In 1997, only about 0.4 percent of U.S. children were reported to have peanut allergy. By 2002 that had doubled to 0.8 percent, and by 2008 it reached 1.4 percent.⁴ A separate analysis estimated that by 2017, about 1.25 million U.S. children and adolescents (2.2 percent) had peanut allergy, with the annual rate of new cases among one-year-olds climbing from roughly 1.7 percent to 5.2 percent between 2001 and 2017.⁵

In adults, the story is less dramatic. The self-reported rate among adults hovered around 1.3 percent in 2008 and was not significantly different from earlier surveys.⁴ But by the time the later adult-focused survey was conducted, 2.9 percent self-reported and 1.8 percent met criteria for a convincing allergy.¹ The jump partly reflects the cohort of children with rising rates growing into adulthood, along with adults developing peanut allergy for the first time, which happens more often than most people realize.

Who Is Most Affected

Peanut allergy does not affect all groups equally. Race and ethnicity play a role in ways researchers are still trying to untangle. Among U.S. children, Black children had the highest rate of convincing peanut allergy at about 3 percent, compared with lower rates in other racial and ethnic groups. Among adults, Asian adults had the highest convincing peanut allergy rate at about 2.9 percent, while White adults had the lowest rate of convincing food allergies overall.⁶ These disparities likely involve a mix of genetic susceptibility, environmental exposures, access to early preventive measures, and differences in how and when allergies get diagnosed.

Age is the other major variable. Children are diagnosed more frequently than adults, and the pediatric rate has been the one rising fastest. But adult-onset peanut allergy is real and not uncommon, a point that surprises many people who assume food allergies are something you either develop in childhood or never get at all.

Sensitization Versus Actual Allergy

One reason the numbers can be confusing is the distinction between sensitization and clinical allergy. A person who shows up positive on a skin-prick test or a blood test for peanut-specific antibodies is “sensitized,” but that does not necessarily mean they will react if they eat a peanut. In one U.K. study, about 10 percent of eight-year-olds were sensitized to peanut, yet only about 2 percent actually had peanut allergy when tested with an oral food challenge.⁷ So the majority of children whose blood says “peanut antibodies present” can eat peanuts without any problem.

This matters because a positive screening test alone can lead to unnecessary dietary restrictions. The field has been moving toward component-resolved diagnostics, which identifies which specific peanut proteins the immune system is reacting to. Antibodies targeting a protein called Ara h 2 are particularly good at predicting who will actually have a clinical reaction. A meta-analysis found that testing for Ara h 2 had a sensitivity of about 83 percent and specificity of about 84 percent for diagnosing actual peanut allergy, outperforming tests for other peanut proteins.⁸ This kind of testing helps allergists figure out who genuinely needs to avoid peanuts and who was flagged by a test that was too broad.

Do Children Outgrow Peanut Allergy?

The short answer is: some do, but most do not, and peanut allergy is far more persistent than many other childhood food allergies. In a longitudinal study following children to age six, egg allergy resolved in about 89 percent of cases, whereas peanut allergy resolved in only about 29 percent.⁹ Children with lower levels of peanut-specific antibodies in their blood are the ones most likely to outgrow it. One study found that among children with very low antibody levels, roughly 73 percent passed an oral challenge, meaning their allergy had resolved. For those with higher levels, the odds were lower.¹⁰

Even among those who outgrow it, recurrence is possible. Some children who pass an oral challenge and resume eating peanuts later lose that tolerance if they stop eating peanuts regularly. This makes the management decision tricky: allergists often recommend that children who have outgrown their allergy continue eating peanut products consistently to keep their tolerance in place.

Why Peanut Allergy Has Become So Common

The rise in peanut allergy over a single generation is too fast to be explained by genetics alone, so researchers have focused on environmental and behavioral factors. One leading idea is the dual allergen exposure hypothesis: eating peanut protein promotes immune tolerance, while exposure through inflamed skin promotes allergic sensitization.¹¹ Children with eczema (atopic dermatitis) have a disrupted skin barrier, and studies have found that exposure to peanut dust in the home environment through that broken skin barrier is a plausible route for developing peanut sensitization and allergy.¹²

In other words, the immune system may first “learn” about peanut through inflamed skin and flag it as a threat, even before the child ever eats a peanut. Past guidelines that told parents to delay introducing peanuts to babies may have inadvertently widened this window of skin-only exposure, giving the immune system the wrong first impression. The reversal of those guidelines is one of the more significant shifts in allergy prevention in decades.

Prevention Through Early Introduction

A landmark trial (the LEAP study) demonstrated that regularly feeding peanut products to high-risk infants starting around four to six months of age dramatically reduces their chance of developing peanut allergy. A recent review in the New England Journal of Medicine noted that early introduction of peanut protein reduces allergy prevalence by about 80 percent, with the benefit diminishing as introduction is delayed.¹³ Current recommendations call for about 2 grams of peanut protein per week for low-risk infants and 4 to 6 grams per week for those at higher risk (such as infants with severe eczema or existing egg allergy).¹⁴

Data from Montreal offers early evidence that these guidelines are making a real-world difference. Among children two years old and younger, the yearly rate of peanut-triggered anaphylaxis dropped significantly after the 2017 early-introduction guidelines were published. The same shift was not seen in older children who had missed the window for early introduction.¹⁵ If this pattern holds across larger populations, the rising prevalence curve may finally start to bend downward for younger cohorts.

How Dangerous Are Peanut Reactions

Peanut is the single most common trigger of food-related anaphylaxis in U.S. children, with emergency department visit rates reaching about 5.85 per 100,000 children in 2014, ahead of tree nuts and all other food allergens.¹⁶ Among pediatric peanut allergy patients whose reactions triggered healthcare visits, over half experienced at least one episode of anaphylaxis.¹⁷

Fatal outcomes, though, are extremely rare. A meta-analysis estimated that peanut-related deaths occur at a rate of about 2.13 per million person-years among people with peanut allergy. For context, the overall rate of fatal food anaphylaxis from any food allergen was about 1.81 per million person-years, meaning peanut accounts for a disproportionate share but the absolute risk remains very low.¹⁸ The same review noted something unsettling: many fatal reactions occurred in people whose previous allergic episodes had been mild, making severity hard to predict. Having asthma, especially poorly controlled asthma, was consistently identified as a major risk factor for fatal reactions.¹⁹

Cross-Reactivity with Tree Nuts, Legumes, and Seeds

Peanuts are legumes, not true nuts, but the immune system does not always respect the botanical distinction. Clinical co-allergy with tree nuts, seeds, and other legumes is common. In one study, about 43 percent of peanut-allergic patients had a confirmed cross-allergy to tree nuts or other legumes, with eczema being a major risk factor for having these additional allergies.²⁰ The molecular basis involves protein families shared across these foods, particularly a group called 2S albumins that are structurally similar in peanuts, tree nuts, and sesame seeds.²¹

Cross-reactivity does not mean everyone with peanut allergy will react to cashews or sesame, but it means the overlap is more common than chance alone would explain. This is one reason allergists often test for a panel of related foods when a peanut allergy is diagnosed.²²

The Everyday Burden

Statistics on prevalence and mortality rates do not capture what it actually feels like to live with peanut allergy. The daily vigilance is substantial. In a multi-country burden study, about a third of caregivers said peanut allergy interfered with day-to-day life “very much” or “completely,” and close to 80 percent of teenagers with peanut allergy said fear of a reaction affected their emotional well-being at least somewhat.²³ Studies of families report that mothers of peanut-allergic children rate their own psychological and physical quality of life significantly worse than fathers do, and the allergic children themselves report poorer quality of life and greater anxiety than their siblings.²⁴

The financial side is no small matter either. Pediatric peanut allergy patients in the U.S. had about 90 percent more emergency department visits than non-allergic peers, and annual healthcare costs were roughly $2,000 to $2,800 higher per patient depending on insurance type, even after accounting for asthma-related expenses.²⁵ That does not include the indirect costs: special food purchases, missed work, and the cognitive load of reading every label at every meal.

Current and Emerging Treatments

For decades, strict avoidance and carrying an epinephrine auto-injector were the only management options. That has started to change. Peanut oral immunotherapy (OIT), which involves eating tiny, gradually increasing amounts of peanut protein under medical supervision, has become the first treatment option to gain real clinical traction. In 2020, the FDA approved Palforzia, a standardized peanut OIT product, for children and adolescents. Research shows that most patients who complete OIT achieve desensitization, meaning they can tolerate a larger accidental exposure without a severe reaction, and some achieve sustained tolerance even after stopping treatment.²⁶

OIT is not without downsides. Allergic side effects during treatment are common, and some are serious enough to require epinephrine. Many allergists now also use store-bought peanut products for OIT rather than the branded product, particularly in preschool-aged children, where accumulating evidence suggests the approach is both safe and potentially more effective the younger you start. Biologic drugs like omalizumab, originally developed for severe asthma, are being studied both as add-ons to OIT and as stand-alone treatments, with early results showing they can reduce the frequency and severity of allergic reactions during immunotherapy.²⁷

Food Labels and Accidental Exposure

Accidental exposure remains the leading cause of allergic reactions in people who already know they have peanut allergy. Precautionary allergen labels like “may contain peanuts,” “made on shared equipment with peanuts,” and “produced in a facility that processes peanuts” are voluntary in the U.S. and are not regulated by the FDA in the same way that ingredient declarations are. A study examining these labels found no meaningful difference in actual peanut contamination among products bearing different precautionary statements: peanut residues turned up in roughly similar proportions whether the label said “may contain,” “shared equipment,” or “shared facility.”²⁸ Both patient behavior and manufacturer omissions contribute to accidental reactions: some consumers ignore precautionary labels after repeated safe experiences, while some manufacturers fail to include a precautionary statement when cross-contamination is a genuine risk.²⁹

The inconsistency of these labels creates a difficult calculus. If a peanut-allergic person avoids every product with any precautionary label, their diet becomes extremely restricted. If they ignore those labels, they accept a small but real risk. Occurrence studies have found that actual peanut contamination turns up in a low but non-negligible percentage of products bearing precautionary labels, around 4 percent in one Canadian analysis.³⁰ Clearer, standardized labeling with actual threshold-based rules has been a longstanding request from the allergy community.

School Policies and Their Effects

Many U.S. schools have adopted some form of peanut restriction, from peanut-free lunch tables to classroom bans to schoolwide policies prohibiting peanut products from home. These policies vary widely in scope and enforcement, and the evidence on which ones actually make a measurable difference is mixed. One large study found that schools with designated peanut-free tables had significantly lower rates of epinephrine use compared with schools without them. However, broader policies like restricting peanuts from all home-packed lunches or banning peanuts from entire classrooms did not show a statistically significant effect on epinephrine administration rates.³¹

That said, peanut-free guidelines do succeed in their primary objective of reducing the amount of peanut in classrooms. A study of school lunchboxes found that peanut turned up in fewer than 1 percent of lunches in classrooms with peanut-free guidelines, versus about 10 percent in classrooms without them.³² The disconnect between these two findings suggests that reducing peanut presence does lower exposure risk, but the effect may not always be large enough to show up in emergency treatment statistics, especially since anaphylaxis at school is already uncommon in absolute terms.

Regional Patterns Within the U.S.

Peanut allergy does not distribute evenly across the country, and researchers are beginning to map regional differences in sensitization patterns. One study found that sensitization to a peanut protein called Ara h 8, which is closely related to birch pollen allergens and tends to cause milder oral symptoms rather than severe systemic reactions, was considerably more common in the northeastern United States than elsewhere.³³ This pattern tracks with the prevalence of birch trees in that region and underscores that not all positive peanut allergy tests reflect the same type of immune response.

A broader analysis of peanut-specific antibodies across regions showed the Western U.S. had the highest overall rate of detectable peanut antibodies (about 96 percent of tested individuals), while the Southeast had the lowest (about 86 percent). Sensitization to the more clinically worrisome proteins, Ara h 2 and Ara h 6, was fairly consistent across most of the country but slightly lower in the Southwest.³⁴ These regional differences may explain why some areas report higher prevalence than others and why the clinical picture can look different depending on which part of the country you live in. A person in New England who tests positive for peanut antibodies may have a birch-pollen-linked sensitivity that causes tingling lips but no danger of anaphylaxis, while a positive test in someone from the Southwest more likely reflects sensitization to the proteins associated with severe reactions.